1. Home
  2. REPL

REPL

Replimune Group Inc.

Logo Replimune Group Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 12:13pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Founded: 2015 Country:
United States
United States
Employees: N/A City: WOBURN
Market Cap: 438.3M IPO Year: 2018
Target Price: $44.50 AVG Volume (30 days): 1.4M
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.16 EPS Growth: N/A
52 Week Low/High: $5.89 - $24.81 Next Earning Date: 05-16-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: